IART CFO confirms operational improvements and niche leadership in a $9 billion addressable market following CEO transition.
Integra LifeSciences reaffirmed its strategic focus on neurosurgery, tissue reconstruction, and ENT markets, representing a $9 billion total addressable market. The company’s CFO, Lea Knight, said the board and former CEO Mojdeh Poul mutually agreed on Poul’s departure, with returning CEO Stuart fully supporting ongoing transformation efforts.
First-quarter results exceeded guidance, reflecting operational improvements such as reduced supply disruptions and better visibility. Knight highlighted niche categories where Integra ranks first or second, reinforcing confidence in the company’s stability and growth trajectory.
The company’s SurgiMend relaunch is nearing completion, aligning with broader efforts to strengthen quality management systems and operational capabilities.